BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

BioStem Technologies, Inc. (OTC: BSEM), a MedTech company focused on placental-derived products for advanced wound care, announced it will release its third quarter 2025 financial results on Thursday, November 13, 2025. The company will host a conference call and webcast at 4:30 PM ET, where CEO Jason Matuszewski and CFO Brandon Poe will provide an overview of the quarter.

Analysis

BioStem Technologies, Inc. (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, has announced its third quarter 2025 financial results will be released on Thursday, November 13, 2025. This release will be followed by a conference call and webcast at 4:30 PM ET, featuring an overview from CEO Jason Matuszewski and CFO Brandon Poe, which will be critical for understanding the company's recent performance.

The company's core business involves the development and commercialization of allografts, utilizing its proprietary BioREtain® processing method, with a portfolio including products like AmnioWrap2™ and VENDAJE®. BioStem Technologies emphasizes its AATB accreditation and FDA-registered facility, highlighting its adherence to cGTP and cGMP standards, which are crucial for credibility and market access in the regenerative therapies space.

Given the neutral sentiment and minimal market impact associated with this pre-announcement, the actual Q3 2025 results and management's subsequent commentary will be the primary catalysts for investor sentiment and stock movement. Investors will be keen to assess revenue trends, profitability, and any updates on product pipeline advancements or commercialization strategies within the competitive healthcare and biotech sector.

Key Decisions for Investors

• Investors should prioritize reviewing BioStem Technologies' Q3 2025 financial results and attending the associated conference call on November 13, 2025, for direct insights into operational performance and strategic direction.
• Focus on key financial metrics such as revenue growth, gross margins, and any updates on product commercialization or regulatory milestones for BSEM's advanced wound care portfolio.
• Monitor management's commentary for future guidance, operational efficiency improvements, and market expansion plans, as these will be crucial for evaluating the company's long-term investment thesis in the MedTech industry.